



iTrack™ to Feature as Part of the Scientific Program of the Australian and New Zealand Glaucoma Society (ANZGS) 2021 Virtual Meeting

Fremont, California, 19 February 2021 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to advise that its proprietary iTrack™ minimally invasive glaucoma surgery (MIGS) procedure, known as ab-interno canaloplasty, will be spotlighted at the Australian and New Zealand Glaucoma Society (ANZGS) 2021 Virtual Meeting, 20-21 February 2021.

Dr. Bentley Logan, a registrar at Liverpool Hospital, Sydney, will present the interim results for iTrack™ ab-interno canaloplasty performed in conjunction with hemigonioscopy assisted transluminal trabeculectomy (GATT) in cases of primary open angle glaucoma (POAG) to ANZGS delegates.

A retrospective consecutive case series, outcome measures include visual acuity, IOP, surgical complications and number of glaucoma medications at one day, one week, one month and 3 months post-surgery.

The Australian and New Zealand Glaucoma Society (ANZGS) is a special interest group of the Royal Australian and New Zealand College of Ophthalmologists (RANZCO), established to represent glaucoma specialists in Australia and New Zealand. Its membership includes academic and non-academic ophthalmologists and is a regional member of the World Glaucoma Association.

For more information on the ANZGS 2021 Virtual Meeting please visit:

<https://anzgsconference.com/>

ABOUT ITRACK™ AB-INTERNO CANALOPLASTY

Canaloplasty was first introduced in 2005 as an alternative to trabeculectomy in the treatment of severe glaucoma, performed via an ab-externo approach. Over time, refinement of the procedure by physicians has seen canaloplasty performed via an ab-interno approach to preserve the conjunctiva and sclera. Today, canaloplasty is commonly deployed in clinical practice via an ab-interno approach in the treatment



of mild and moderate glaucoma. Unlike other minimally invasive glaucoma surgery (MIGS) procedures, which bypass the natural drainage system or remove tissue, ab-interno canaloplasty is a tissue-sparing, implant-free procedure that acts to re-establish the function of the eye's natural drainage system – achieving an average reduction in IOP of 30%¹ while also preserving the viability of future treatment options. As a result, an increasing number of surgeons are turning to ab-interno canaloplasty to manage their mild-moderate glaucoma patients.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

Media enquires:

Kate Hunt
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

Investor enquires:

Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com